These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 11034097)

  • 41. [Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens].
    Prikler L; Scandella E; Men Y; Engeler DS; Diener PA; Gillessen S; Ludewig B; Schmid HP
    Aktuelle Urol; 2004 Aug; 35(4):326-30. PubMed ID: 15459874
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vaccination with a chaperone complex based on PSCA and GRP170 adjuvant enhances the CTL response and inhibits the tumor growth in mice.
    Huo W; Ye J; Liu R; Chen J; Li Q
    Vaccine; 2010 Aug; 28(38):6333-7. PubMed ID: 20637304
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines.
    Rocchi P; Boudouresque F; Zamora AJ; Muracciole X; Lechevallier E; Martin PM; Ouafik L
    Cancer Res; 2001 Feb; 61(3):1196-206. PubMed ID: 11221851
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Induction of cytotoxic T lymphocytes from the peripheral blood of a hepatocellular carcinoma patient using melanoma antigen-1 (MAGE-1) peptide.
    Lu J; Leng X; Peng J; Mou D; Pang X; Shang X; Chen W
    Chin Med J (Engl); 2002 Jul; 115(7):1002-5. PubMed ID: 12150730
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A novel DNA/peptide combined vaccine induces PSCA-specific cytotoxic T-lymphocyte responses and suppresses tumor growth in experimental prostate cancer.
    Zhang KQ; Yang F; Ye J; Jiang M; Liu Y; Jin FS; Wu YZ
    Urology; 2012 Jun; 79(6):1410.e7-13. PubMed ID: 22513035
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of natural antigenic peptides of a human gastric signet ring cell carcinoma recognized by HLA-A31-restricted cytotoxic T lymphocytes.
    Suzuki K; Sahara H; Okada Y; Yasoshima T; Hirohashi Y; Nabeta Y; Hirai I; Torigoe T; Takahashi S; Matsuura A; Takahashi N; Sasaki A; Suzuki M; Hamuro J; Ikeda H; Wada Y; Hirata K; Kikuchi K; Sato N
    J Immunol; 1999 Sep; 163(5):2783-91. PubMed ID: 10453022
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gene and peptide analyses of newly defined lung cancer antigens recognized by HLA-A2402-restricted tumor-specific cytotoxic T lymphocytes.
    Yamada A; Kawano K; Koga M; Takamori S; Nakagawa M; Itoh K
    Cancer Res; 2003 Jun; 63(11):2829-35. PubMed ID: 12782588
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene.
    Hogan KT; Eisinger DP; Cupp SB; Lekstrom KJ; Deacon DD; Shabanowitz J; Hunt DF; Engelhard VH; Slingluff CL; Ross MM
    Cancer Res; 1998 Nov; 58(22):5144-50. PubMed ID: 9823325
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells.
    Tomita Y; Imai K; Senju S; Irie A; Inoue M; Hayashida Y; Shiraishi K; Mori T; Daigo Y; Tsunoda T; Ito T; Nomori H; Nakamura Y; Kohrogi H; Nishimura Y
    Cancer Sci; 2011 Apr; 102(4):697-705. PubMed ID: 21231984
    [TBL] [Abstract][Full Text] [Related]  

  • 50. NY-ESO-1 may be a potential target for lung cancer immunotherapy.
    Lee L; Wang RF; Wang X; Mixon A; Johnson BE; Rosenberg SA; Schrump DS
    Cancer J Sci Am; 1999; 5(1):20-5. PubMed ID: 10188057
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of HLA-A*2402-restricted epitope peptide derived from ERas oncogene expressed in human scirrhous gastric cancer.
    Iwauchi T; Tanaka H; Yamazoe S; Yashiro M; Yoshii M; Kubo N; Muguruma K; Sawada T; Ohira M; Hirakawa K
    Cancer Sci; 2011 Apr; 102(4):683-9. PubMed ID: 21205089
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte.
    Lethé B; van der Bruggen P; Brasseur F; Boon T
    Melanoma Res; 1997 Aug; 7 Suppl 2():S83-8. PubMed ID: 9578421
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Retargeting of T cells to prostate stem cell antigen expressing tumor cells: comparison of different antibody formats.
    Feldmann A; Stamova S; Bippes CC; Bartsch H; Wehner R; Schmitz M; Temme A; Cartellieri M; Bachmann M
    Prostate; 2011 Jun; 71(9):998-1011. PubMed ID: 21541976
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibitory effect of RNA pool complexity on stimulatory capacity of RNA-pulsed dendritic cells.
    Javorovic M; Wilde S; Zobywalski A; Noessner E; Lennerz V; Wölfel T; Schendel DJ
    J Immunother; 2008 Jan; 31(1):52-62. PubMed ID: 18157012
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
    Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
    Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of prostate-specific G-protein coupled receptor as a tumor antigen recognized by CD8(+) T cells for cancer immunotherapy.
    Matsueda S; Wang M; Weng J; Li Y; Yin B; Zou J; Li Q; Zhao W; Peng W; Legras X; Loo C; Wang RF; Wang HY
    PLoS One; 2012; 7(9):e45756. PubMed ID: 23029225
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein.
    Pinilla-Ibarz J; May RJ; Korontsvit T; Gomez M; Kappel B; Zakhaleva V; Zhang RH; Scheinberg DA
    Leukemia; 2006 Nov; 20(11):2025-33. PubMed ID: 16990779
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein.
    Kiessling A; Stevanovic S; Füssel S; Weigle B; Rieger MA; Temme A; Rieber EP; Schmitz M
    Br J Cancer; 2004 Mar; 90(5):1034-40. PubMed ID: 14997204
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PSCA mRNA expression in preoperatively negative prostate biopsies predicts incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z; Ma W; Zeng G; Qi D
    J Surg Oncol; 2011 Nov; 104(6):672-8. PubMed ID: 21674503
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen.
    Murphy G; Tjoa B; Ragde H; Kenny G; Boynton A
    Prostate; 1996 Dec; 29(6):371-80. PubMed ID: 8977634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.